Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 20, 2024

Impact of Tumor-Infiltrating Lymphocyte Density on Outcomes in Patients With TNBC Treated With Anthracycline-Free Neoadjuvant Chemotherapy

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy
Clin. Cancer Res 2024 Mar 11;[EPub Ahead of Print], M Martín, R Yoder, R Salgado, M Del Monte-Millán, EL Alvarez, I Echavarría, JM Staley, AP O'Dea, LE Nye, SR Stecklein, C Bueno Muiño, Y Jerez-Gilarranz, M Cebollero, O Bueno, JÁ Garcia-Saenz, F Moreno, U Bohn, H Gomez, T Massarrah, QJ Khan, AK Godwin, S López-Tarruella, P Sharma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading